230 related articles for article (PubMed ID: 15683605)
1. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis.
Folmes CD; Clanachan AS; Lopaschuk GD
Curr Atheroscler Rep; 2005 Feb; 7(1):63-70. PubMed ID: 15683605
[TBL] [Abstract][Full Text] [Related]
2. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
Wang W; Lopaschuk GD
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1123-34. PubMed ID: 18035928
[TBL] [Abstract][Full Text] [Related]
3. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.
Jaswal JS; Keung W; Wang W; Ussher JR; Lopaschuk GD
Biochim Biophys Acta; 2011 Jul; 1813(7):1333-50. PubMed ID: 21256164
[TBL] [Abstract][Full Text] [Related]
4. Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease.
Lopaschuk GD; Stanley WC
Cardiovasc Drugs Ther; 2006 Dec; 20(6):433-9. PubMed ID: 17136490
[TBL] [Abstract][Full Text] [Related]
5. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
[TBL] [Abstract][Full Text] [Related]
6. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions.
Calvani M; Reda E; Arrigoni-Martelli E
Basic Res Cardiol; 2000 Apr; 95(2):75-83. PubMed ID: 10826498
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid oxidation in the reperfused ischemic heart.
Kantor PF; Dyck JR; Lopaschuk GD
Am J Med Sci; 1999 Jul; 318(1):3-14. PubMed ID: 10408755
[TBL] [Abstract][Full Text] [Related]
8. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
Lopaschuk GD
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
[TBL] [Abstract][Full Text] [Related]
9. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
[TBL] [Abstract][Full Text] [Related]
10. Targets for modulation of fatty acid oxidation in the heart.
Lopaschuk GD
Curr Opin Investig Drugs; 2004 Mar; 5(3):290-4. PubMed ID: 15083595
[TBL] [Abstract][Full Text] [Related]
11. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts.
Lopaschuk GD; Wambolt RB; Barr RL
J Pharmacol Exp Ther; 1993 Jan; 264(1):135-44. PubMed ID: 8380856
[TBL] [Abstract][Full Text] [Related]
12. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Kantor PF; Lucien A; Kozak R; Lopaschuk GD
Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420
[TBL] [Abstract][Full Text] [Related]
13. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart.
Sambandam N; Lopaschuk GD
Prog Lipid Res; 2003 May; 42(3):238-56. PubMed ID: 12689619
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.
McCormack JG; Barr RL; Wolff AA; Lopaschuk GD
Circulation; 1996 Jan; 93(1):135-42. PubMed ID: 8616920
[TBL] [Abstract][Full Text] [Related]
15. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
[TBL] [Abstract][Full Text] [Related]
16. Changes in substrate metabolism in isolated mouse hearts following ischemia-reperfusion.
Aasum E; Hafstad AD; Larsen TS
Mol Cell Biochem; 2003 Jul; 249(1-2):97-103. PubMed ID: 12956404
[TBL] [Abstract][Full Text] [Related]
17. Role of metabolically active drugs in the management of ischemic heart disease.
Schofield RS; Hill JA
Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
[TBL] [Abstract][Full Text] [Related]
18. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions.
Stanley WC; Lopaschuk GD; Hall JL; McCormack JG
Cardiovasc Res; 1997 Feb; 33(2):243-57. PubMed ID: 9074687
[TBL] [Abstract][Full Text] [Related]
19. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
Lopaschuk GD
Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481
[TBL] [Abstract][Full Text] [Related]
20. The heart is better protected against myocardial infarction in the fed state compared to the fasted state.
Liepinsh E; Makrecka M; Kuka J; Makarova E; Vilskersts R; Cirule H; Sevostjanovs E; Grinberga S; Pugovics O; Dambrova M
Metabolism; 2014 Jan; 63(1):127-36. PubMed ID: 24140100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
